Assertio Holdings Inc. announced that its wholly owned subsidiary, Spectrum Pharmaceuticals, Inc., has entered into an amended and restated supply agreement with Hanmi Pharmaceutical Co. Ltd. for the supply of ROLVEDON drug substance. The amendment establishes long-term pricing following the expiration of fixed pricing provisions in October 2025, reflecting a mid-single digit percentage reduction to the price paid by Spectrum. The new price will remain fixed for the remainder of Spectrum's license agreement with Hanmi, with the potential for price adjustments based on specified cost increases or global market volume thresholds. Spectrum will provide annual forecasted purchase plans, with at least fifty percent of each plan designated as binding. No minimum purchase requirements are included in the agreement, and other supply terms remain materially unchanged.